Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536508 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Phase 3 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 627
- Enrollment target
NCT02536508: Completed Phase 3 study, sponsored by Pearl Therapeutics.
NCT02536508 is a Phase 3 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 627 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02536508, a Phase 3 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 627 participants
- Enrollment target
Study Summary
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Primary Outcome
Percent change from baseline in BMD of the lumbar spine T-Score at Week 52.
Interventions
- DRUG BGF MDI 320/14.4/9.6 μg
- DRUG GFF MDI 14.4/9.6 μg
- DRUG BFF MDI 320/9.6 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2015-08-10 |
| Est. Completion | 2017-09-12 |
| Phase | Phase 3 |
What the finished NCT02536508 record still lists
NCT02536508 is an interventional study that assigns participants to a tested intervention. The registered 627 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 3 interventions - of which BGF MDI 320/14.4/9.6 μg is the first listed.
NCT02536508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02536508 about?
NCT02536508 is a clinical study titled "Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease". Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
What is the current status of trial NCT02536508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 627 participants. The study started on 2015-08-10. Estimated completion is 2017-09-12.
What interventions are being tested in trial NCT02536508?
The interventions under investigation include: BGF MDI 320/14.4/9.6 μg (DRUG), GFF MDI 14.4/9.6 μg (DRUG), BFF MDI 320/9.6 μg (DRUG).
Who is sponsoring clinical trial NCT02536508?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02536508's enrollment target sits among peer trials
627 586th of 2000 higher than 1,415 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI